Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.

Autor: Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Saadati M; Saadati Solutions, Ladenburg, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Ottone T; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.; Santa Lucia Foundation, Neuro-Oncohematology, I.R.C.C.S., Rome, Italy., Amadori S; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Prior TW; Case Western Reserve University, Cleveland, OH, USA., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Division of Hematologic Malignancies, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland., Krzykalla J; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. konstanze.doehner@uniklinik-ulm.de.

Publikováno v: Leukemia [Leukemia] 2022 Sep; Vol. 36 (9), pp. 2218-2227. Date of Electronic Publication: 2022 Aug 03.

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Autor: Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Du L; Novartis Pharmaceuticals, Cambridge, MA, USA., Luck TJ; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland., Voso MT; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Amadori S; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Prior TW; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Savoie L; University of Calgary, Calgary, AB, Canada., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau and Jose Carreras Leukemia Research Institute, Autonomus University of Barcelona, Barcelona, Spain., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland., Sanz MA; Hospital Universitario la Fe, Hematology Department, Department of Medicine, University of Valencia, Valencia, Spain., Jansen JH; Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, The Netherlands., Niederwieser D; Hematology and Oncology, University of Leipzig, Leipzig, Germany., Fischer T; Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. konstanze.doehner@uniklinik-ulm.de.

Publikováno v: Leukemia [Leukemia] 2022 Jan; Vol. 36 (1), pp. 90-99. Date of Electronic Publication: 2021 Jul 28.

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Autor: Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA. rlarson@medicine.bsd.uchicgo.edu., Mandrekar SJ; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA., Huebner LJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA., Sanford BL; Alliance Statistics and Data Center, Duke University, Durham, NC, USA., Laumann K; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA., Geyer S; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Prior TW; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Döhner K; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Marcucci G; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Voso MT; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Klisovic RB; Emory University School of Medicine, Atlanta, GA, USA., Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wei AH; Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institute, Autonomous University of Barcelona, Barcelona, Spain., Sanz MA; Department of Hematology, Hospital Universitario y Politécnico La Fe and Department of Medicine, University of Valencia, Valencia, Spain., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., de Witte T; Radboud University Medical Centre, Nijmegen, Netherlands., Niederwieser D; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Krauter J; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Schlenk RF; Department of Internal Medicine III, University of Ulm, Ulm, Germany.; NCT Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Serve H; Department of Medicine II, Hematology/Oncology, Goethe University Hospital Frankfurt, Frankfurt/Main, Germany., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Amadori S; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Gathmann I; Novartis Pharma AG, Basel, Switzerland., Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2539-2551. Date of Electronic Publication: 2021 Mar 02.

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.

Autor: Pamuk, Gulsum E.¹ (AUTHOR) gulsum.pamuk@fda.hhs.gov, Ehrlich, Lori A.¹ (AUTHOR)

Publikováno v: Cancers. Nov2024, Vol. 16 Issue 21, p3615. 22p.

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

Autor: Döhner K; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Thiede C; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany., Jahn N; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Gambietz A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Research Center, University of Chicago, Chicago, IL., Prior TW; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Marcucci G; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Jones D; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Krauter J; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Voso MT; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata,' Rome, Italy., Ottone T; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata,' Rome, Italy., Nomdedeu JF; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Jose Carreras Leukemia Research Institutes, Autonomus University of Barcelona, Barcelona, Spain., Mandrekar SJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., Klisovic RB; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wei AH; Department of Clinical Hematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Jose Carreras Leukemia Research Institutes, Autonomus University of Barcelona, Barcelona, Spain., Sanz MA; Instituto de Investigación Sanitaria La Fe, University of Valencia, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain., Brandwein JM; Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada., de Witte T; Radboud University Medical Centre, Nijmegen, The Netherlands., Jansen JH; Laboratory Hematology, Deptartment of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Niederwieser D; Department of Hematology, Oncology, and Hemostasis, University of Leipzig, Leipzig, Germany., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Schlenk RF; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Serve H; Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany., Ehninger G; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany., Amadori S; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata,' Rome, Italy., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland; and., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland; and., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA., Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Publikováno v: Blood [Blood] 2020 Jan 30; Vol. 135 (5), pp. 371-380.